Turnstone Biologics Corp.

NasdaqGM:TSBX Stock Report

Market Cap: US$10.6m

Turnstone Biologics Valuation

Is TSBX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TSBX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TSBX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TSBX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TSBX?

Key metric: As TSBX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for TSBX. This is calculated by dividing TSBX's market cap by their current book value.
What is TSBX's PB Ratio?
PB Ratio0.2x
BookUS$43.64m
Market CapUS$10.64m

Price to Book Ratio vs Peers

How does TSBX's PB Ratio compare to its peers?

The above table shows the PB ratio for TSBX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1x
FNCH Finch Therapeutics Group
1.4xn/aUS$18.4m
KZIA Kazia Therapeutics
n/an/aUS$16.5m
APTX Aptinyx
0.4xn/aUS$6.5m
UBX Unity Biotechnology
1.4x55.2%US$19.5m
TSBX Turnstone Biologics
0.2x-11.6%US$10.6m

Price-To-Book vs Peers: TSBX is expensive based on its Price-To-Book Ratio (0.2x) compared to the peer average (0.1x).

Price to Book Ratio vs Industry

How does TSBX's PB Ratio compare vs other companies in the US Biotechs Industry?

60 CompaniesPrice / BookEstimated GrowthMarket Cap
Industry Avg.1.8x28.4%
TSBX Turnstone Biologics
 0.2x-11.6%US$10.64m
GRAL GRAIL
0.2x35.7%US$550.38m
IMAB I-Mab
0.4x1.8%US$79.81m
TSBX 0.2xIndustry Avg. 1.8xNo. of Companies82PB01.63.24.86.48+
60 CompaniesEstimated GrowthMarket Cap
Industry Avg.1.8x28.4%
TSBX Turnstone Biologics
 0.2x-11.6%US$10.64m
No more companies

Price-To-Book vs Industry: TSBX is good value based on its Price-To-Book Ratio (0.2x) compared to the US Biotechs industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is TSBX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TSBX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate TSBX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TSBX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.48
US$3.38
+601.5%
11.1%US$3.75US$3.00n/a2
Nov ’25US$0.50
US$2.42
+385.3%
57.5%US$3.75US$0.50n/a3
Oct ’25US$0.54
US$6.58
+1,128.5%
39.3%US$10.00US$3.75n/a3
Sep ’25US$0.70
US$6.58
+837.8%
39.3%US$10.00US$3.75n/a3
Aug ’25US$2.44
US$12.67
+419.1%
45.3%US$20.00US$6.00n/a3
Jul ’25US$2.65
US$12.67
+378.0%
45.3%US$20.00US$6.00n/a3
Jun ’25US$2.61
US$12.67
+385.3%
45.3%US$20.00US$6.00n/a3
May ’25US$2.60
US$13.00
+400.0%
44.0%US$20.00US$6.00n/a3
Apr ’25US$2.85
US$13.00
+356.1%
44.0%US$20.00US$6.00n/a3
Mar ’25US$4.62
US$13.67
+195.8%
42.4%US$20.00US$6.00n/a3
Feb ’25US$2.78
US$16.00
+475.5%
18.4%US$20.00US$13.00n/a3
Jan ’25US$2.55
US$16.00
+528.7%
18.4%US$20.00US$13.00n/a3
Dec ’24US$2.11
US$16.00
+658.3%
18.4%US$20.00US$13.00n/a3
Nov ’24US$3.55
US$17.00
+378.9%
17.3%US$20.00US$13.00US$0.503
Oct ’24US$3.94
US$17.00
+331.5%
17.3%US$20.00US$13.00US$0.543
Sep ’24US$11.92
US$17.00
+42.6%
17.3%US$20.00US$13.00US$0.703

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Collegium Pharmaceutical

US$967.5m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.41

7D

0.5%

1Y

17.1%

IQVIA Holdings

US$35.3b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$197.60

7D

-2.6%

1Y

-5.7%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.86

7D

-5.2%

1Y

8.0%